Urogen Pharma Ltd (NASDAQ:URGN) Q2 2022 Earnings Conference Call August 11, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director, IR Elizabeth Barrett - President, CEO & Director Mark Schoenberg - Chief Medical Officer Jeffrey Bova - Chief Commercial Officer Dong Kim - CFO Conference Call Participants Christopher Howerton - Jefferies Raghuram Selvaraju - H.C. Wainwright & Co. Boris Peaker - Cowen and Company Matthew Kaplan - Ladenburg Thalmann & Co. Leland Gershell - Oppenheimer Operator ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Don Kim - CFO Conference Call Participants Ram Selvaraju - H.C. Wainwright Boris Peaker - Cowen Chris Howerton - Jefferies Matt Kaplan - Ladenburg Thalmann Leland Gershell - Oppenheimer Anita Dushyanth - Berenberg Capital Operator Good morning, ladies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2021 Earnings Conference Call March 21, 2022 10:00 AM ET Company Participants Vincent Perrone - Senior Director of Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Boris Peaker - Cowen Christopher Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Operator Good morning, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____________to ________________ Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter) Israe ...

NOVEMBER 2021 UROGEN PHARMA Forward Looking Statements 2 This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential market opportunity of Jelmyto in LG-UTUC; commercial plans for favorable market access and both patient and physician uptake; expected interest in prescribing Jelmyto; the continued successful launch of Jelmyto; the potential of UroGen's proprietary RTGel™ technolog ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2021 Earnings Conference Call November 15, 2021 10:00 AM ET Company Participants Lee Roth - IR Liz Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer Molly Henderson - CFO Conference Call Participants Chris Howerton - Jefferies Paul Choi - Goldman Sachs Matt Kaplan - Ladenburg Thalmann Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and thank you for standing by. And welcome to UroGen Pharma' ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Sara Sherman - Head of Investor Relations Liz Barrett - President and CEO Jeff Bova - Chief Commercial Officer Mark Schoenberg - Chief Medical Officer Molly Henderson - CFO Conference Call Participants Leland Gershell - Oppenheimer Chris Howerton - Jefferies Ram Selvaraju - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Paul Choi - Goldman Sachs Operator Good morning, ladies and gentlemen, and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38079 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or o ...